. . . "Studie AURORA Rosuvastatin a kardiovaskul\u00E1rn\u00ED p\u0159\u00EDhody u hemodialyzovan\u00FDch nemocn\u00FDch"@cs . "statins; endstage renal disease; hemodialysis; cardiovascular events"@en . "AURORA study: Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis"@en . . . "RIV/00216224:14110/09:00037948!RIV10-MSM-14110___" . "Studie AURORA Rosuvastatin a kardiovaskul\u00E1rn\u00ED p\u0159\u00EDhody u hemodialyzovan\u00FDch nemocn\u00FDch"@cs . . . "RIV/00216224:14110/09:00037948" . "CZ - \u010Cesk\u00E1 republika" . "2"^^ . "Studie AURORA Rosuvastatin a kardiovaskul\u00E1rn\u00ED p\u0159\u00EDhody u hemodialyzovan\u00FDch nemocn\u00FDch" . . "2"^^ . "2"^^ . "1213-807X" . . "V\u00EDtovec, Ji\u0159\u00ED" . "Interven\u010Dn\u00ED a akutn\u00ED kardiologie" . "14110" . . . . . "344307" . "The AURORA study included 2,776 patients who had been in a regular dialysis programme for at least 3 months. Following randomization, the patients received rosuvastatin at a dose of 10 mg/day or placebo. The combined primary endpoint was cardiovascular death, nonfatal myocardial infarction, or stroke. The study failed to demonstrate an effect of treatment with rosuvastatin on reducing cardiovascular events in dialysis patients."@en . . "Do studie AURORA bylo za\u0159azeno 2 776 pacient\u016F, kte\u0159\u00ED byli za\u0159azeni do chronick\u00E9ho dialyza\u010Dn\u00EDho programu nejm\u00E9n\u011B 3 m\u011Bs\u00EDce. Po randomizaci nemocn\u00ED dost\u00E1vali rosuvastatin v d\u00E1vce 10 mg/den a nebo placebo. Kombinovan\u00FD prim\u00E1rn\u00ED c \u00EDl bylo \u00FAmrt\u00ED z kardiovaskul\u00E1rn\u00ED p\u0159\u00ED\u010Diny, nefat\u00E1ln\u00ED infarkt myokardu \u010Di mozkov\u00E1 p\u0159\u00EDhoda. Studie neprok\u00E1zala vliv l\u00E9\u010Dby rosuvastatinem na sn\u00ED\u017Een\u00ED KV p\u0159\u00EDhod u dialyzovan\u00FDch nemocn\u00FDch."@cs . . "5" . "8" . . "Z(MSM0021622402)" . "Do studie AURORA bylo za\u0159azeno 2 776 pacient\u016F, kte\u0159\u00ED byli za\u0159azeni do chronick\u00E9ho dialyza\u010Dn\u00EDho programu nejm\u00E9n\u011B 3 m\u011Bs\u00EDce. Po randomizaci nemocn\u00ED dost\u00E1vali rosuvastatin v d\u00E1vce 10 mg/den a nebo placebo. Kombinovan\u00FD prim\u00E1rn\u00ED c \u00EDl bylo \u00FAmrt\u00ED z kardiovaskul\u00E1rn\u00ED p\u0159\u00ED\u010Diny, nefat\u00E1ln\u00ED infarkt myokardu \u010Di mozkov\u00E1 p\u0159\u00EDhoda. Studie neprok\u00E1zala vliv l\u00E9\u010Dby rosuvastatinem na sn\u00ED\u017Een\u00ED KV p\u0159\u00EDhod u dialyzovan\u00FDch nemocn\u00FDch." . . "\u0160pinar, Jind\u0159ich" . "[6807C3AB4175]" . "Studie AURORA Rosuvastatin a kardiovaskul\u00E1rn\u00ED p\u0159\u00EDhody u hemodialyzovan\u00FDch nemocn\u00FDch" . "AURORA study: Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis"@en .